-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LSP8oIwtVZ9RriE/rzTpE1fA7bn7Vkd9KG8nRGvcCnY1WzzGVIV5hnN6TOho18Iw WSQ93SHqfDXCWH4WsgULWA== 0000950123-98-001544.txt : 19980218 0000950123-98-001544.hdr.sgml : 19980218 ACCESSION NUMBER: 0000950123-98-001544 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980217 SROS: NASD GROUP MEMBERS: UBS (LUX) EQUITY INVEST-BIOTECH GROUP MEMBERS: UBS ASSET MANAGEMENT NEW YORK INC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: VIROPHARMA INC CENTRAL INDEX KEY: 0000946840 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232789550 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-48239 FILM NUMBER: 98541029 BUSINESS ADDRESS: STREET 1: 76 GREAT VALLEY PARKWAY STREET 2: PO BOX 5000 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 6106510200 MAIL ADDRESS: STREET 1: 76 GREAT VALLEY PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: UBS ASSET MANAGEMENT NEW YORK INC CENTRAL INDEX KEY: 0000881153 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 1345 AVENUE OF THE AMERICAS STREET 2: WEST 54TH & 55TH ST - 49TH FL CITY: NEW YORK STATE: NY ZIP: 10105 BUSINESS PHONE: 2126497100 SC 13G 1 SCHEDULE 13G 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viropharma, Inc. ----------------------------------------- (Name of Issuer) Common Stock ----------------------------------------- (Title of Class of Securities) 928241108 ----------------------------------------- (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person UBS Asset Management (New York) Inc. Tax ID: 13-2725861 2. Check the Appropriate Box if a Member of a Group a.[ ] b.[ ] 3. SEC Use Only 4. Citizenship or Place of Organization New York 5. Sole Voting Power: -0- Number of Shares 6. Shared Voting Power: Beneficially -0- Owned by Each 7. Sole Dispositive Power: Reporting 590,000 Person With 8. Shared Dispositive Power: -0- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 590,000 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9) 5.15% 12. Type of Reporting Person 1A -2- 3 CUSIP Number: 928241108 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above person UBS (Lux) Equity Invest-Biotech, a Subfund of UBS (Lux) Equity Invest 2. Check the Appropriate Box if a Member of a Group a.[ ] b.[ ] 3. SEC Use Only 4. Citizenship or Place of Organization Luxembourg 5. Sole Voting Power: 590,000 Number of Shares 6. Shared Voting Power: Beneficially -0- Owned by Each 7. Sole Dispositive Power: Reporting -0- Person With 8. Shared Dispositive Power: -0- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 590,000 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares 11. Percent of Class Represented by Amount in Row (9) 5.15% 12. Type of Reporting Person 00 -3- 4 Item 1(a) Name of Issuer: Viropharma, Inc. (the "Company") (b) Address of Issuer's Principal Executive Offices: 76 Great Valley Parkway Malvern, PA 19355 Item 2(a)-(c) Name, Principal Business Address, and Citizenship of Persons Filing: UBS Asset Management (New York) Inc. 1345 Avenue of the Americas New York, New York 10105 UBS (Lux) Equity Invest-Biotech, a subfund of UBS (Lux) Equity Invest c/o INTRAG International Equity Invest (Company for Fund Management) S.A. Luxembourg (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 928241108 Item 3. This statement is filed pursuant to Rule 13d-1(b)(1) and 13d-1(b)(2). UBS Asset Management (New York) Inc. is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. UBS (Lux) Equity Invest-Biotech, a subfund of UBS (Lux) Equity Invest is an investment fund organized under Luxembourg law. -4- 5 Item 4. Ownership. UBS Asset Management (New York) Inc. and UBS (Lux) Equity Invest-Biotech, a subfund of UBS (Lux) Equity Invest beneficially own 590,000 shares of the Company's Common Stock (representing approximately 5.15% of the outstanding shares of such Common Stock). UBS Asset Management (New York) Inc. possesses the power to dispose of and direct the disposition of all 590,000 shares. UBS (Lux) Equity Invest-Biotech, a subfund of UBS (Lux) Equity Invest possesses the power to vote or direct the vote of all 590,000 shares. The holding listed above are as of December 31, 1997. Item 5. Ownership of Five Percent or Less of a Class. Not Applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. See Item 4. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company. Not Applicable. Item 8. Identification and Classification of Members of the Group. Not Applicable. Item 9. Notice of Dissolution of the Group. Not Applicable. Item 10. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. -5- 6 After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. UBS Asset Management (New York) Inc. By: /s/ Joseph Scavo February 13, 1998 -------------------------- --------------------------- Title: Director of Compliance Date INTRAG International Equity Invest (Company For Fund Management) S.A. By: /s/ Gilbert Schintgen February 13, 1998 -------------------------- --------------------------- Title: Director Date By: /s/ Manuel Hauser February 13, 1998 -------------------------- --------------------------- Title: Director Date -6- -----END PRIVACY-ENHANCED MESSAGE-----